Evidence map›Paper›PMID 39840380›Full record

ArticleHemaSphere2025

Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia.

Femke M Hormann, Anna Østergaard, Stijn van den Broek, Aurélie Boeree, Cesca van de Ven, Gabriele Escherich, Edwin Sonneveld, Judith M Boer, Monique L den Boer

Abstract read
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Femke M HormannPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID https://orcid.org/0000-0001-5164-3047
Anna ØstergaardPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID 0000-0003-2443-421X
Stijn van den BroekPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.
Aurélie BoereePrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.
Cesca van de VenPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID 0000-0002-9797-9539
Gabriele EscherichCOALL-German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia Hamburg Germany.
Edwin SonneveldPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID https://orcid.org/0000-0002-1869-0957
Judith M BoerPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID 0000-0003-4848-7789
Monique L den BoerPrincess Máxima Center for Pediatric Oncology Utrecht Netherlands.ORCID https://orcid.org/0000-0002-5795-2921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrachromosomal amplification of chromosome 21 (iAMP21) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in children is a high-risk subtype for which targeted drugs are lacking. In this study, we determined the frequency of secondary lesions in 28 iAMP21 BCP-ALL patient samples and investigated cellular sensitivity for candidate-targeted drugs. iAMP21 was enriched in

Identifiers

PMID39840380
PMCPMC11746935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.